Lupin Pharmaceutical Inc., the US subsidiary of Lupin Ltd, has entered in a strategic licensing agreement with MonoSol Rx. The company would develop multiple pediatric products utilising MonoSol Rx's proprietary PharmFilm drug delivery technology.
MonoSol Rx's PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film.
For patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms, PharmFilm technology provides a minimally invasive alternative to pills, injections, and gels, with the goal of helping patients adhere to their prescribed treatment regimens in order to improve their health.
The technology could offer potential to support pediatric patients in particular, many of whom have difficulty with the currently available oral or injectable dosing of needed medications.
